PDF   Print   View All
November 05, 2003
European Symposium To Be Held November 9-12, 2003

Philadelphia, PA, Wednesday, November 05, 2003: Hemispherx Biopharma, Inc. (AMEX: HEB) announced today that the Company will be giving a presentation of new in vitro data on Alferon N® as a potent inhibitor of SARS coronavirus at the 14th International Antiviral Symposium and Workshop on Sunday, November 9, 2003 at 4:15 pm. in Antalya, Turkey.

Dr. Dale L. Barnard, PhD, Professor at the Institute for Antiviral Research of Utah State University, will present the abstract. The presentation will discuss the promising new results obtained from National Institutes of Health sponsored, independent laboratory research on the human SARS agent and Alferon N®, the Company’s lead drug, and compare its potency with other potential SARS treatments.

About the 14th International Antiviral Symposium and Workshop.
The meeting will focus on antiviral compounds for new emerging viral infections, such as severe acute respiratory syndrome (SARS). Viral diseases, including HBV, HCV, HIV and other important pathogenic viruses, are a problem of enormous proportions around the world. The 14th International Antiviral Symposium is an independent peer-reviewed conference which does not receive any financial support from the Company.

About the Conference Organizers
Chair of the meeting, Professor Yung-Chi Cheng, Professor of Pharmacology at Yale University Medical Center, has served as a founding member of the Scientific Advisory Board of Hemispherx Biopharma. His stated mission:” There are always new emerging viral infections and new antiviral compounds or antiviral research are needed to fight against these emerging classes of infectious viruses. In the era of developments in the pathogenesis and the management of viral infections, the Symposium can further extend knowledge in this era and can open new horizon to scientists and clinicians in the field.”

About Alferon N®
Alferon N® (Interferon alfa-n3, human leukocyte derived) is a highly purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high purified alpha interferon. It is the only natural-source, multispecies alpha interferon currently sold in the U.S. for the treatment of refractory papilloma infections (HPV) and is also approved for sale by various regulatory agencies worldwide. By contrast, recombinant, non-natural source, interferon is composed of only one form and can cause allergic (antibody formation) reactions in man.

About Hemispherx
Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based chronic disorders. Its flagship products include Alferon and the experimental immunotherapeutics/antivirals Ampligen and Oragens. These novel proteins, approved for a category of STD infection, and experimental nucleic acids are being developed for globally important chronic viral diseases and disorders of the immune system including HPV, HIV, CFS and Hepatitis. Its platform technology includes large and small agent components for potential treatment of various chronic viral infections. Hemispherx has approximately 400 patents comprising its core intellectual property estate, a fully commercialized product (Alferon N) and GMP certified manufacturing facilities for its novel pharma products. For more information please visit www.hemispherx.net

Hemispherx Biopharma, Inc.,
Dianne Will, Investor Relations
(518) 398-6222, Fax: (518) 398-6223

HEB's Web Site: www.hemispherx.net

Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the company (including AmpligenÒ and Oragensä) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Clinical trials for other potential indications of the approved biologic AlferonÒ do not imply that the product will ever be specifically approved commercially for these other treatment indications including SARS. The Alferon® asset for overseas sales for a category of STD is currently being acquired by the Company as part of a multi-step purchase contract of inventory, intellectual property, commercial licenses and GMP approved facilities, which house the biological operations.